eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes

M. A. Couto, S. S L Harwig, James S Cullor, J. P. Hughes, R. I. Lehrer

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We purified a novel cysteine-rich antibiotic peptide, eNAP-2 (M(r), ~6,500), from acid extracts of equine neutrophils by sequential gel filtration and reversed-phase high-performance liquid chromatography and determined its partial N-terminal amino acid sequence. Although its cysteine motif distinguished eNAP-2 from all other currently known endogenous antibiotic peptides, including defensins and granulins, it showed substantial sequence similarity to WDNM1, a putative member of the four-disulfide-core protein family that also includes animal and human antiproteases, snake venom neurotoxins, and rat and mouse whey proteins. The antibacterial properties of eNAP-2 were tested against several equine uterine pathogens, namely, Streptococcus zooepidemicus, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Killing of S. zooepidemicus was very efficient, as evidenced by a 94% decrease in numbers of CFU per milliliter after exposure to 100 μg of eNAP-2 per ml (~15 μM) for 2 h. Exposure of E. coli and P. aeruginosa to 200 μg of eNAP-2 per ml for 2 h resulted in 90.2 and 77.6% reduction, respectively, in the numbers of CFU per milliliter. Bacteriostasis, without bactericidal activity, occurred after K. pneumoniae was incubated with 200 μg of eNAP-2 per ml. Additional studies will be required in other species and cell types to determine whether eNAP-2 is restricted to equine neutrophils or is the index member of a larger family of endogenous antibiotics.

Original languageEnglish (US)
Pages (from-to)5042-5047
Number of pages6
JournalInfection and Immunity
Volume60
Issue number12
StatePublished - 1992

Fingerprint

Horses
Cysteine
Leukocytes
Peptides
Streptococcus equi
Klebsiella pneumoniae
Anti-Bacterial Agents
Pseudomonas aeruginosa
Neutrophils
Escherichia coli
Defensins
Snake Venoms
Neurotoxins
Reverse-Phase Chromatography
equine neutrophil antibiotic peptide 2
Protease Inhibitors
Disulfides
Gel Chromatography
Amino Acid Sequence
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Immunology

Cite this

Couto, M. A., Harwig, S. S. L., Cullor, J. S., Hughes, J. P., & Lehrer, R. I. (1992). eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. Infection and Immunity, 60(12), 5042-5047.

eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. / Couto, M. A.; Harwig, S. S L; Cullor, James S; Hughes, J. P.; Lehrer, R. I.

In: Infection and Immunity, Vol. 60, No. 12, 1992, p. 5042-5047.

Research output: Contribution to journalArticle

Couto, MA, Harwig, SSL, Cullor, JS, Hughes, JP & Lehrer, RI 1992, 'eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes', Infection and Immunity, vol. 60, no. 12, pp. 5042-5047.
Couto, M. A. ; Harwig, S. S L ; Cullor, James S ; Hughes, J. P. ; Lehrer, R. I. / eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. In: Infection and Immunity. 1992 ; Vol. 60, No. 12. pp. 5042-5047.
@article{a1dc9c392e564b17ba96665e53efddd7,
title = "eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes",
abstract = "We purified a novel cysteine-rich antibiotic peptide, eNAP-2 (M(r), ~6,500), from acid extracts of equine neutrophils by sequential gel filtration and reversed-phase high-performance liquid chromatography and determined its partial N-terminal amino acid sequence. Although its cysteine motif distinguished eNAP-2 from all other currently known endogenous antibiotic peptides, including defensins and granulins, it showed substantial sequence similarity to WDNM1, a putative member of the four-disulfide-core protein family that also includes animal and human antiproteases, snake venom neurotoxins, and rat and mouse whey proteins. The antibacterial properties of eNAP-2 were tested against several equine uterine pathogens, namely, Streptococcus zooepidemicus, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Killing of S. zooepidemicus was very efficient, as evidenced by a 94{\%} decrease in numbers of CFU per milliliter after exposure to 100 μg of eNAP-2 per ml (~15 μM) for 2 h. Exposure of E. coli and P. aeruginosa to 200 μg of eNAP-2 per ml for 2 h resulted in 90.2 and 77.6{\%} reduction, respectively, in the numbers of CFU per milliliter. Bacteriostasis, without bactericidal activity, occurred after K. pneumoniae was incubated with 200 μg of eNAP-2 per ml. Additional studies will be required in other species and cell types to determine whether eNAP-2 is restricted to equine neutrophils or is the index member of a larger family of endogenous antibiotics.",
author = "Couto, {M. A.} and Harwig, {S. S L} and Cullor, {James S} and Hughes, {J. P.} and Lehrer, {R. I.}",
year = "1992",
language = "English (US)",
volume = "60",
pages = "5042--5047",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes

AU - Couto, M. A.

AU - Harwig, S. S L

AU - Cullor, James S

AU - Hughes, J. P.

AU - Lehrer, R. I.

PY - 1992

Y1 - 1992

N2 - We purified a novel cysteine-rich antibiotic peptide, eNAP-2 (M(r), ~6,500), from acid extracts of equine neutrophils by sequential gel filtration and reversed-phase high-performance liquid chromatography and determined its partial N-terminal amino acid sequence. Although its cysteine motif distinguished eNAP-2 from all other currently known endogenous antibiotic peptides, including defensins and granulins, it showed substantial sequence similarity to WDNM1, a putative member of the four-disulfide-core protein family that also includes animal and human antiproteases, snake venom neurotoxins, and rat and mouse whey proteins. The antibacterial properties of eNAP-2 were tested against several equine uterine pathogens, namely, Streptococcus zooepidemicus, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Killing of S. zooepidemicus was very efficient, as evidenced by a 94% decrease in numbers of CFU per milliliter after exposure to 100 μg of eNAP-2 per ml (~15 μM) for 2 h. Exposure of E. coli and P. aeruginosa to 200 μg of eNAP-2 per ml for 2 h resulted in 90.2 and 77.6% reduction, respectively, in the numbers of CFU per milliliter. Bacteriostasis, without bactericidal activity, occurred after K. pneumoniae was incubated with 200 μg of eNAP-2 per ml. Additional studies will be required in other species and cell types to determine whether eNAP-2 is restricted to equine neutrophils or is the index member of a larger family of endogenous antibiotics.

AB - We purified a novel cysteine-rich antibiotic peptide, eNAP-2 (M(r), ~6,500), from acid extracts of equine neutrophils by sequential gel filtration and reversed-phase high-performance liquid chromatography and determined its partial N-terminal amino acid sequence. Although its cysteine motif distinguished eNAP-2 from all other currently known endogenous antibiotic peptides, including defensins and granulins, it showed substantial sequence similarity to WDNM1, a putative member of the four-disulfide-core protein family that also includes animal and human antiproteases, snake venom neurotoxins, and rat and mouse whey proteins. The antibacterial properties of eNAP-2 were tested against several equine uterine pathogens, namely, Streptococcus zooepidemicus, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Killing of S. zooepidemicus was very efficient, as evidenced by a 94% decrease in numbers of CFU per milliliter after exposure to 100 μg of eNAP-2 per ml (~15 μM) for 2 h. Exposure of E. coli and P. aeruginosa to 200 μg of eNAP-2 per ml for 2 h resulted in 90.2 and 77.6% reduction, respectively, in the numbers of CFU per milliliter. Bacteriostasis, without bactericidal activity, occurred after K. pneumoniae was incubated with 200 μg of eNAP-2 per ml. Additional studies will be required in other species and cell types to determine whether eNAP-2 is restricted to equine neutrophils or is the index member of a larger family of endogenous antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=0026493723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026493723&partnerID=8YFLogxK

M3 - Article

C2 - 1452336

AN - SCOPUS:0026493723

VL - 60

SP - 5042

EP - 5047

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 12

ER -